On June 24, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, held its Download Day investor meeting where it provided updated pipeline guidance and partnership updates. The company, which specializes in decoding biology to industrialize drug discovery, announced seven clinical trial readouts expected within the next 18 months, including Phase 2 data for REC-994 and REC-2282, and Phase 1 data for Target Epsilon. Recursion also highlighted its partnership with Bayer, revealing that Bayer will become the first external beta-user of Recursion's LOWE software for drug discovery and development. Additionally, the company is on track to complete 25 unique multi-modal data packages for Bayer by the third quarter of 2024. The Download Day featured prominent speakers from the industry and provided insights into Recursion's technological advancements, such as achieving significant lab throughput increases and building a genome-scale transcriptomics knockout map. The company also emphasized its commitment to leveraging machine learning and massive computational scale to advance medicine.

On June 24, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, held its Download Day investor meeting where it provided updated pipeline guidance and partnership updates. The company, which specializes in decoding biology to industrialize drug discovery, announced seven clinical trial readouts expected within the next 18 months, including Phase 2 data for REC-994 and REC-2282, and Phase 1 data for Target Epsilon. Recursion also highlighted its partnership with Bayer, revealing that Bayer will become the first external beta-user of Recursion's LOWE software for drug discovery and development. Additionally, the company is on track to complete 25 unique multi-modal data packages for Bayer by the third quarter of 2024. The Download Day featured prominent speakers from the industry and provided insights into Recursion's technological advancements, such as achieving significant lab throughput increases and building a genome-scale transcriptomics knockout map. The company also emphasized its commitment to leveraging machine learning and massive computational scale to advance medicine.